New Insights on Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3: What a 1,013-Participant Study Found

JDD (2021), this phase iii randomized trial evaluating 1,013 human participants investigated: Two identical phase 3 trials (NCT03168321 and NCT03168334) and pooled post hoc analyses have established real-world benefits and safety of a polymeric tazarotene 0.045% lotion formulation in patients with moderate-to-severe acne. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?

To find out, researchers writing in Journal of drugs in dermatology : JDD conducted a phase iii randomized trial evaluating 1,013 real-world participants. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.

Tazarotene 0.045% lotion is efficacious and well tolerated in female and male adolescents and adults with moderate-to-severe acne. doi:10.36849/JDD.6070. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.

Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.

Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.